Noting that cancer cells are often resistant to xCT inhibition by GSH deficiency, Okazaki et al. [53] conducted a synthetic lethal screening of a drug library to identify the agents that sensitize cancer cells resistant to GSH deficiency to the xCT inhibitor SAS, and identified dyclonine, an oral anesthetic that covalently inhibits ALDH. Here, LDHA is linked to cancer.